Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Condition: ER-Positive HER2-Negative Breast Cancer Interventions: Drug: AZD9833; Drug: AZD9833 Placebo; Drug: Anastrozole; Drug: Anastrozole placebo; Drug: Letrozole; Drug: Letrozole placebo; Drug: Palbociclib; Drug: Abemaciclib; Drug: Luteinizing hormone-releasing hormone (LHRH) agonist Sponsor: AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 16, 2021 Category: Research Source Type: clinical trials
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Condition: Breast Cancer Stage IV Interventions: Drug: Palbociclib; Drug: Ribociclib; Drug: Abemaciclib; Drug: Letrozole; Drug: Anastrozole; Drug: Tamoxifen; Drug: Fulvestrant; Drug: Exemestane; Drug: Alpelisib Sponsor: Blokhin's Russian Cancer Research Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 21, 2021 Category: Research Source Type: clinical trials
